Comparative financing analysis and political economy of noncommunicable diseases

Mihajlo Jakovljevic, Melitta Jakab, Ulf Gerdtham, David McDaid, Seiritsu Ogura, Elena Varavikova, Joav Merrick, R. Ádány, Albert Okunade, Thomas E. Getzen

Research output: Review article

2 Citations (Scopus)

Abstract

The pandemic of chronic non-communicable diseases (NCDs) poses substantial challenges to the health financing sustainability in high-income and low/middle income countries (LMICs). The aim of this review is to identify the bottle neck inefficiencies in NCDs attributable spending and propose sustainable health financing solutions. The World Health Organization (WHO) introduced the “best buy” concept to scale up the core intervention package against NCDs targeted for LMICs. Population- and individual-based NCD best buy interventions are projected at US$170 billion over 2011–2025. Appropriately designed health financing arrangements can be powerful enablers to scale up the NCD best buys. Rapidly developing emerging nations dominate the landscape of LMICs. Their capability and willingness to invest resources for eradicating NCDs could strengthen WHO outreach efforts in Asia, Africa, and Latin America, much beyond current capacities. There has been a declining trend in international donor aid intended to cope with NCDs over the past decade. There is also a serious misalignment of these resources with the actual needs of recipient countries. Globally, the momentum towards the financing of intersectoral actions is growing, and this presents a cost-effective solution. A budget discrepancy of 10:1 in WHO and multilateral agencies remains in donor aid in favour of communicable diseases compared to NCDs. LMICs are likely to remain a bottleneck of NCDs imposed financing sustainability challenge in the long-run. Catastrophic household health expenditure from out of pocket spending on NCDs could plunge almost 150 million people into poverty worldwide. This epidemiological burden coupled with population ageing presents an exceptionally serious sustainability challenge, even among the richest countries which are members of the Organization for Economic Co-operation and Development (OECD). Strategic and political leadership of WHO and multilateral agencies would likely play essential roles in the struggle that has just begun.

Original languageEnglish
Pages (from-to)722-727
Number of pages6
JournalJournal of Medical Economics
Volume22
Issue number8
DOIs
Publication statusPublished - aug. 3 2019

Fingerprint

Healthcare Financing
Health Expenditures
Latin America
Pandemics
Budgets
Poverty
Population
Developing Countries
Communicable Diseases
Costs and Cost Analysis

ASJC Scopus subject areas

  • Health Policy

Cite this

Jakovljevic, M., Jakab, M., Gerdtham, U., McDaid, D., Ogura, S., Varavikova, E., ... Getzen, T. E. (2019). Comparative financing analysis and political economy of noncommunicable diseases. Journal of Medical Economics, 22(8), 722-727. https://doi.org/10.1080/13696998.2019.1600523

Comparative financing analysis and political economy of noncommunicable diseases. / Jakovljevic, Mihajlo; Jakab, Melitta; Gerdtham, Ulf; McDaid, David; Ogura, Seiritsu; Varavikova, Elena; Merrick, Joav; Ádány, R.; Okunade, Albert; Getzen, Thomas E.

In: Journal of Medical Economics, Vol. 22, No. 8, 03.08.2019, p. 722-727.

Research output: Review article

Jakovljevic, M, Jakab, M, Gerdtham, U, McDaid, D, Ogura, S, Varavikova, E, Merrick, J, Ádány, R, Okunade, A & Getzen, TE 2019, 'Comparative financing analysis and political economy of noncommunicable diseases', Journal of Medical Economics, vol. 22, no. 8, pp. 722-727. https://doi.org/10.1080/13696998.2019.1600523
Jakovljevic M, Jakab M, Gerdtham U, McDaid D, Ogura S, Varavikova E et al. Comparative financing analysis and political economy of noncommunicable diseases. Journal of Medical Economics. 2019 aug. 3;22(8):722-727. https://doi.org/10.1080/13696998.2019.1600523
Jakovljevic, Mihajlo ; Jakab, Melitta ; Gerdtham, Ulf ; McDaid, David ; Ogura, Seiritsu ; Varavikova, Elena ; Merrick, Joav ; Ádány, R. ; Okunade, Albert ; Getzen, Thomas E. / Comparative financing analysis and political economy of noncommunicable diseases. In: Journal of Medical Economics. 2019 ; Vol. 22, No. 8. pp. 722-727.
@article{46c305615a884c8096e22c1be2251830,
title = "Comparative financing analysis and political economy of noncommunicable diseases",
abstract = "The pandemic of chronic non-communicable diseases (NCDs) poses substantial challenges to the health financing sustainability in high-income and low/middle income countries (LMICs). The aim of this review is to identify the bottle neck inefficiencies in NCDs attributable spending and propose sustainable health financing solutions. The World Health Organization (WHO) introduced the “best buy” concept to scale up the core intervention package against NCDs targeted for LMICs. Population- and individual-based NCD best buy interventions are projected at US$170 billion over 2011–2025. Appropriately designed health financing arrangements can be powerful enablers to scale up the NCD best buys. Rapidly developing emerging nations dominate the landscape of LMICs. Their capability and willingness to invest resources for eradicating NCDs could strengthen WHO outreach efforts in Asia, Africa, and Latin America, much beyond current capacities. There has been a declining trend in international donor aid intended to cope with NCDs over the past decade. There is also a serious misalignment of these resources with the actual needs of recipient countries. Globally, the momentum towards the financing of intersectoral actions is growing, and this presents a cost-effective solution. A budget discrepancy of 10:1 in WHO and multilateral agencies remains in donor aid in favour of communicable diseases compared to NCDs. LMICs are likely to remain a bottleneck of NCDs imposed financing sustainability challenge in the long-run. Catastrophic household health expenditure from out of pocket spending on NCDs could plunge almost 150 million people into poverty worldwide. This epidemiological burden coupled with population ageing presents an exceptionally serious sustainability challenge, even among the richest countries which are members of the Organization for Economic Co-operation and Development (OECD). Strategic and political leadership of WHO and multilateral agencies would likely play essential roles in the struggle that has just begun.",
keywords = "BRICS, chronic disease, EM7, emerging markets, health financing, low- and middle-income countries, Non-communicable diseases, sustainability",
author = "Mihajlo Jakovljevic and Melitta Jakab and Ulf Gerdtham and David McDaid and Seiritsu Ogura and Elena Varavikova and Joav Merrick and R. {\'A}d{\'a}ny and Albert Okunade and Getzen, {Thomas E.}",
year = "2019",
month = "8",
day = "3",
doi = "10.1080/13696998.2019.1600523",
language = "English",
volume = "22",
pages = "722--727",
journal = "Journal of Medical Economics",
issn = "1369-6998",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Comparative financing analysis and political economy of noncommunicable diseases

AU - Jakovljevic, Mihajlo

AU - Jakab, Melitta

AU - Gerdtham, Ulf

AU - McDaid, David

AU - Ogura, Seiritsu

AU - Varavikova, Elena

AU - Merrick, Joav

AU - Ádány, R.

AU - Okunade, Albert

AU - Getzen, Thomas E.

PY - 2019/8/3

Y1 - 2019/8/3

N2 - The pandemic of chronic non-communicable diseases (NCDs) poses substantial challenges to the health financing sustainability in high-income and low/middle income countries (LMICs). The aim of this review is to identify the bottle neck inefficiencies in NCDs attributable spending and propose sustainable health financing solutions. The World Health Organization (WHO) introduced the “best buy” concept to scale up the core intervention package against NCDs targeted for LMICs. Population- and individual-based NCD best buy interventions are projected at US$170 billion over 2011–2025. Appropriately designed health financing arrangements can be powerful enablers to scale up the NCD best buys. Rapidly developing emerging nations dominate the landscape of LMICs. Their capability and willingness to invest resources for eradicating NCDs could strengthen WHO outreach efforts in Asia, Africa, and Latin America, much beyond current capacities. There has been a declining trend in international donor aid intended to cope with NCDs over the past decade. There is also a serious misalignment of these resources with the actual needs of recipient countries. Globally, the momentum towards the financing of intersectoral actions is growing, and this presents a cost-effective solution. A budget discrepancy of 10:1 in WHO and multilateral agencies remains in donor aid in favour of communicable diseases compared to NCDs. LMICs are likely to remain a bottleneck of NCDs imposed financing sustainability challenge in the long-run. Catastrophic household health expenditure from out of pocket spending on NCDs could plunge almost 150 million people into poverty worldwide. This epidemiological burden coupled with population ageing presents an exceptionally serious sustainability challenge, even among the richest countries which are members of the Organization for Economic Co-operation and Development (OECD). Strategic and political leadership of WHO and multilateral agencies would likely play essential roles in the struggle that has just begun.

AB - The pandemic of chronic non-communicable diseases (NCDs) poses substantial challenges to the health financing sustainability in high-income and low/middle income countries (LMICs). The aim of this review is to identify the bottle neck inefficiencies in NCDs attributable spending and propose sustainable health financing solutions. The World Health Organization (WHO) introduced the “best buy” concept to scale up the core intervention package against NCDs targeted for LMICs. Population- and individual-based NCD best buy interventions are projected at US$170 billion over 2011–2025. Appropriately designed health financing arrangements can be powerful enablers to scale up the NCD best buys. Rapidly developing emerging nations dominate the landscape of LMICs. Their capability and willingness to invest resources for eradicating NCDs could strengthen WHO outreach efforts in Asia, Africa, and Latin America, much beyond current capacities. There has been a declining trend in international donor aid intended to cope with NCDs over the past decade. There is also a serious misalignment of these resources with the actual needs of recipient countries. Globally, the momentum towards the financing of intersectoral actions is growing, and this presents a cost-effective solution. A budget discrepancy of 10:1 in WHO and multilateral agencies remains in donor aid in favour of communicable diseases compared to NCDs. LMICs are likely to remain a bottleneck of NCDs imposed financing sustainability challenge in the long-run. Catastrophic household health expenditure from out of pocket spending on NCDs could plunge almost 150 million people into poverty worldwide. This epidemiological burden coupled with population ageing presents an exceptionally serious sustainability challenge, even among the richest countries which are members of the Organization for Economic Co-operation and Development (OECD). Strategic and political leadership of WHO and multilateral agencies would likely play essential roles in the struggle that has just begun.

KW - BRICS

KW - chronic disease

KW - EM7

KW - emerging markets

KW - health financing

KW - low- and middle-income countries

KW - Non-communicable diseases

KW - sustainability

UR - http://www.scopus.com/inward/record.url?scp=85068514808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068514808&partnerID=8YFLogxK

U2 - 10.1080/13696998.2019.1600523

DO - 10.1080/13696998.2019.1600523

M3 - Review article

VL - 22

SP - 722

EP - 727

JO - Journal of Medical Economics

JF - Journal of Medical Economics

SN - 1369-6998

IS - 8

ER -